Abstract
BACKGROUND: Botulinum toxin Type A (BoNT-A) injection is the most widely performed nonsurgical cosmetic procedure in the United Kingdom. PrabotulinumtoxinA is a new BoNT-A, recently licensed in the United Kingdom, for treating moderate-to-severe glabellar lines in adults under 65. Although clinical trials have established safety and efficacy, real-world data can help clinicians translate study findings into practice and support prabotulinumtoxinA use in a more diverse patient population. OBJECTIVES: To understand the real-world patient experience and patient perceptions of prabotulinumtoxinA performance for treatment of the glabellar region. METHODS: In this single-center survey study, a single injector administered prabotulinumtoxinA for the treatment of glabellar lines to real-world patients presenting for BoNT-A treatment. Two weeks later, patients received surveys asking about their experience through email. There were no incentives for participation. Responses returned within 5 weeks of treatment were included. RESULTS: From February to June 2023, 457 patients received prabotulinumtoxinA injections for glabellar line treatment. Survey response rate was 56% (254/457 patients). For most patients, treatment onset was 2 to 3 days following injection and peak response occurred after 7 to 10 days. Adverse effects were minimal, with 67% of patients experiencing none. Among survey respondents, 83% rated their treatment positively (5-point satisfaction scale), and 72% would choose prabotulinumtoxinA again. CONCLUSIONS: These data support safety and effectiveness of prabotulinumtoxinA in a diverse, real-world population, and confirm patient satisfaction among experienced BoNT-A patients, as well as suggest a rapid time to onset and peak effect.